about
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Initial therapy of chronic lymphocytic leukemia.
@en
type
label
Initial therapy of chronic lymphocytic leukemia.
@en
prefLabel
Initial therapy of chronic lymphocytic leukemia.
@en
P1433
P1476
Initial therapy of chronic lymphocytic leukemia.
@en
P2093
Paula Cramer
P304
P356
10.1053/J.SEMINONCOL.2016.02.005
P577
2016-02-09T00:00:00Z